Viatris sees bigger future in biosimilars — and a bigger return

Viatris, and Mylan before it, saw biosimilars as a way to grow its business and create a differentiation among its competitors.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.